Adimmune Corporation
Adimmune Corporation, a leading biopharmaceutical company based in Taiwan (TW), has been at the forefront of vaccine development since its establishment in 1965. With a strong focus on the research, production, and distribution of vaccines, Adimmune has made significant strides in enhancing public health both locally and internationally. The company is renowned for its innovative vaccine solutions, including those for influenza and other infectious diseases, which are distinguished by their high efficacy and safety profiles. Adimmune's commitment to quality and research excellence has positioned it as a key player in the global vaccine market. Over the years, Adimmune has achieved numerous milestones, solidifying its reputation as a trusted provider of vaccines. Its strategic operations extend beyond Taiwan, reaching various regions, thereby contributing to global health initiatives and responding to emerging health challenges.
DitchCarbon Score
How does Adimmune Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Adimmune Corporation's score of 21 is lower than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Adimmune Corporation's reported carbon emissions
In 2022, Adimmune Corporation reported total carbon emissions of approximately 17,271,000 kg CO2e, comprising 5,211,000 kg CO2e from Scope 1 and 12,060,000 kg CO2e from Scope 2 emissions. This marked an increase from 15,978,000 kg CO2e in 2021, which included 4,337,000 kg CO2e from Scope 1 and 11,641,000 kg CO2e from Scope 2. In 2020, the company recorded total emissions of about 12,480,000 kg CO2e, with Scope 1 emissions at 3,215,000 kg CO2e and Scope 2 emissions at 9,265,000 kg CO2e. As of 2023, Adimmune has not disclosed specific emissions data, nor have they set any formal reduction targets or commitments under the Science Based Targets initiative (SBTi). The company has not reported any Scope 3 emissions, indicating a focus primarily on direct and indirect emissions from their operations. Adimmune Corporation's emissions data is not cascaded from any parent organisation, and all reported figures are derived directly from their own disclosures. The company continues to monitor its emissions and is committed to improving its environmental performance, although specific initiatives or pledges have not been detailed.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | |
|---|---|---|---|
| Scope 1 | 3,215,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 9,265,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Adimmune Corporation is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
